BlossomHill Therapeutics, Inc.
BLSMHealthcare|Biotechnology|US
$13.50
+1.15 (+9.31%)
DCF Value
$3.85
Tangible Book / Share
$3.02
Cash / Share
$3.51
About
Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.
Stock Price
-15.6%(1Y)
1M
-20.0%
3M
-15.6%
6M
-15.6%
YTD
-15.6%
1Y
-15.6%
3Y
-15.6%
5Y
-15.6%
Pipeline Summary
2 total trials2
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 2
Active Trials (2)
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
NCT06501196Leukemia
Phase 1Recruiting
Enrollment: 170 participants
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
NCT06706076NSCLC (Advanced Non-small Cell Lung Cancer)
Phase 1Phase 2Recruiting
Enrollment: 675 participants
Key Facts
Market Cap$392.6M
Employees69
CEOJing Rong Jean Cui
IPO DateAug 7, 2026
Beta0.00
52-Week Range$11.02 – $27.99
Avg Volume226,612
ExchangeNASDAQ
Websitebhtherapeutics.com
Ownership
Float77.7%
Shares Outstanding29.1M
Recent Insider Trades
GORDON CARL LBUY
Aug 10, 2026625,000 shares @ $16.00
GORDON CARL LCONVERSION
Aug 10, 20261,049,283 shares
GORDON CARL LCONVERSION
Aug 10, 20261,039,996 shares
GORDON CARL LCONVERSION
Aug 10, 20261,049,283 shares
GORDON CARL LCONVERSION
Aug 10, 20261,039,996 shares
Peers
Recent News
BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting
Nov 4, 2026 · globenewswire.com
BlossomHill Therapeutics to Present at Guggenheim's 3rd Annual Healthcare Innovations Conference
Nov 3, 2026 · globenewswire.com
BlossomHill Therapeutics: A Deliberate Beachhead Trading Back At Its IPO Price
Oct 28, 2026 · seekingalpha.com
BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer
Oct 22, 2026 · globenewswire.com
BlossomHill Therapeutics (NASDAQ:BLSM) Shares Down 4.9% – Time to Sell?
Oct 2, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 03:59 AM